N4 Pharma’s Nuvec® Targets Lung Cancer Cells

AI SummaryClose X

N4 Pharma announced positive results from its collaboration with SRI, achieving targeted delivery of therapeutic RNA to non-small cell lung cancer cells using its Nuvec® system. The Nuvec® particles were functionalized with a targeting molecule, demonstrating selective uptake and activity only in the targeted cells compared to untargeted Nuvec®. This validates Nuvec®'s potential as a delivery system for RNA therapeutics across multiple diseases. The global RNA therapeutics market was valued at $13.7 billion in 2023 and is forecast to reach $18.0 billion by 2028. The company believes this sets it apart from other RNA delivery methods.

Disclaimer*

UK 100

Latest directors dealings